- Home
- CYD vs MREO Comparison
CYD vs MREO Comparison
Compare CYD & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYD
- MREO
- Stock Information
- Founded
- CYD 1951
- MREO 2015
- Country
- CYD Singapore
- MREO United Kingdom
- Employees
- CYD N/A
- MREO N/A
- Industry
- CYD Industrial Machinery/Components
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CYD Industrials
- MREO Health Care
- Exchange
- CYD Nasdaq
- MREO Nasdaq
- Market Cap
- CYD 609.7M
- MREO 438.8M
- IPO Year
- CYD 1994
- MREO N/A
- Fundamental
- Price
- CYD $24.85
- MREO $1.66
- Analyst Decision
- CYD
- MREO Strong Buy
- Analyst Count
- CYD 0
- MREO 5
- Target Price
- CYD N/A
- MREO $7.20
- AVG Volume (30 Days)
- CYD 203.6K
- MREO 3.5M
- Earning Date
- CYD 08-11-2025
- MREO 08-12-2025
- Dividend Yield
- CYD 1.59%
- MREO N/A
- EPS Growth
- CYD 17.49
- MREO N/A
- EPS
- CYD 1.12
- MREO N/A
- Revenue
- CYD $2,621,360,849.00
- MREO N/A
- Revenue This Year
- CYD $6.43
- MREO N/A
- Revenue Next Year
- CYD $11.20
- MREO $52.34
- P/E Ratio
- CYD $21.23
- MREO N/A
- Revenue Growth
- CYD 6.03
- MREO N/A
- 52 Week Low
- CYD $8.61
- MREO $1.58
- 52 Week High
- CYD $26.10
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- CYD 69.10
- MREO 29.70
- Support Level
- CYD $23.40
- MREO $2.77
- Resistance Level
- CYD $24.67
- MREO $3.05
- Average True Range (ATR)
- CYD 1.19
- MREO 0.18
- MACD
- CYD -0.01
- MREO -0.06
- Stochastic Oscillator
- CYD 99.73
- MREO 9.76
About CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).